Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies by Nogueira, António José M. et al.
Abstract. Chronic kidney disease (CKD) is a long-term
condition in which the kidneys do not work correctly. It has a
high prevalence and represents a serious hazard to human health
and estimated to affects hundreds of millions of people. Diabetes
and hypertension are the two principal causes of CKD. The
progression of CKD is characterized by the loss of renal cells
and their replacement by extracellular matrix (ECM),
independently of the associated disease. Thus, one of the
consequences of CKD is glomerulosclerosis and
tubulointerstitial fibrosis caused by an imbalance between
excessive synthesis and reduced breakdown of the ECM. There
are many molecules and cells that are associated with
progression of renal fibrosis e.g. angiotensin II (Ang II).
Therefore, in order to understand the biopathology of renal
fibrosis and for the evaluation of new treatments, the use of
animal models is crucial such as: surgical, chemical and
physical models, spontaneous models, genetic models and in
vitro models. However, there are currently no effective treatments
for preventing the progression of renal fibrosis. Therefore it is
essential to improve our knowledge of the cellular and molecular
mechanisms of the progress of renal fibrosis in order to achieve
a reversion/elimination of renal fibrosis.
Chronic kidney disease (CKD) represents a serious hazard to
human health, and has a high prevalence. In developed
countries, it is estimated that more than 10% of adults present
some degree of CKD (1). Despite a varied initial evolution,
which is related to the diversity of its aetiologies – namely
genetics, autoimmune-related infections, environmental factors,
diet, and drugs – progressive renal disease frequently results in
renal fibrosis and finally in renal failure. The mechanisms
implicated in renal fibrosis are still poorly understood, and
existing therapies are ineffective or only slightly successful,
hence it is essential to understand the pathophysiological
mechanisms underlying the usual development of CKD, and to
discover and better understand new strategies for treating this
disease. In order to study the biopathology of this disease and
to evaluate new treatments, animal models are required. The
perfect animal model for renal disease research should have
human-like renal anatomy, haemodynamics and physiology, as
well as enabling the determination of relevant renal,
biochemical and haemodynamic parameters. In all probability,
no species can consistently meet all these requirements, and
the experimental plan and other constraints often determine the
choice of animal models for particular research applications.
With this in mind, this review aims to describe and analyze
animal models of renal fibrosis and suggest new areas of
research.
Renal Fibrosis: Aetiology and Pathophysiology
Diabetes and hypertension are currently the two principal
causes of CKD (2), among other causes such as infectious
glomerulonephritis, renal vasculitis, ureteral obstruction,
genetic alterations, autoimmune diseases (1) and drugs (3,
4). In general, diabetes causes glomerular hypertension by
reducing the afferent arteriolar resistance while stimulating
the efferent arterioles (2). Thus, elevated glomerular
capillary pressure is one of the major factors in progressive
renal sclerosis (5). Diabetes and hypertension gradually lead
to glomerular expansion, which causes endothelial
dysfunction and haemodynamic changes: loss of the
glomerular basement membrane electric charge and its
thickening, a decreased number of podocytes, foot-process
effacement and mesangial distension have been shown to
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underlie the initial glomerular injury, which probably leads
to glomerulosclerosis. (1). The reaction of renal tissue to
damage resembles the common wound-healing response that
occurs in other tissues. However, the repair and recovery of
tissue function does not always happen, so why do some
wounds heal and others progress to fibrosis? The answer is
difficult because there are a variety of factors that influence
the response to injury (6). The glomerulus is a structure with
multiple interactions of endothelial, mesangial and epithelial
cells that form the filtering capillary loops (5). Progression
of CKD is evidenced by the loss of renal cells and their
replacement by extracellular matrix (ECM) (5, 7) in
glomeruli and interstitium. Chronic glomerulonephritis,
tubulointerstitial disease, hypertension, or diabetic
nephropathy (8), occurring independently of the associated
disease, arise as a consequence of increased
synthesis/reduced degradation of ECM (5, 7, 9). The
pathogenesis of glomerulosclerosis has strong similarities to
the pathogenesis of tubulointerstitial fibrosis. In general,
glomerulosclerosis and tubulointerstitial fibrosis are the
result of an imbalance between the excessive synthesis and
decreased breakdown of the ECM, which may result from a
normal wound-healing response becoming deregulated, with
an uncontrolled inflammatory response and myofibroblast
proliferation (10). In this sense matrix metalloproteinases
and their tissue inhibitors are determinants of ECM
accumulation (9). In addition, Hewitson suggests that
fibrosis may also result from a collapse of the renal
parenchyma (6). The end-stage of renal disease is manifested
by the presence of glomerulosclerosis, vascular sclerosis and
tubulointerstitial fibrosis. Indeed, glomerulosclerosis is
initially attributable to the disproportionate production of
ground substance proteins by mesangial cells, associated
with a reduction in the extracellular proteolytic activity
generated by these cells (2). In this sense, the excessive
glomerular production of transforming growth factor (TGF)-
β, the key cytokine in the development of glomerulosclerosis
and tubulointerstitial fibrosis (11), stimulates mesangial cells
(2, 12), and is probably the most potent inducer of epithelial–
mesenchymal transition (13). Activation of TGFβ results in
a self-maintaining cycle of matrix deposition, through an
increase in protein synthesis and a decrease in matrix protein
degradation, resulting in persistent tissue injury (11, 14). The
diminution of this cytokine bioactivity reduces ECM
deposition and the development of fibrosis in experimental
renal injury (11). On the other hand, an increase in oxidative
stress has been associated with increased mesangial
expression of TGFβ (2) and also stimulation by angiotensin
II (Ang II) (15). Endothelial and mesangial oxidant stress
related to diabetes and systemic hypertension may also
interfere with the production of glomerular nitric oxide,
possibly reducing the activity of nitric oxide and thus
impairing its protective effect in the process of
glomerulosclerosis (2). However, there are additional non-
haemodynamic factors, such as growth factors, proto-
oncogenes, infiltrating macrophages, proteinuria, reactive
oxygen species, hyperlipidaemia and vasoactive substances,
such as Ang II and endothelin, that contribute to renal
sclerosis. Nevertheless the activity of these factors probably
depends on the type of initial damage, the age of the
individual when the injury occurs, and complex genetic
factors, all of which influence the process of sclerosis (5).
Thus, renal fibrosis can also be considered as
tubulointerstitial fibrosis, since this process features tubular
destruction. Curiously glomerulosclerosis, despite being a
disease with its own entity, causes tubulointerstitial fibrosis
by inducing tubular destruction. Although it is assumed that
tubulointerstitial fibrosis accelerates the degeneration of
injured nephrons and these may also interfere with
neighbouring healthy tubules, contributing to the progression
of kidney fibrosis (16). Existing knowledge about the
progression of renal fibrosis is extraordinarily complex and
therefore it is difficult to prevent or even eliminate renal
fibrosis. Nevertheless, as referred to by Fogo, this is
theoretically possible (5). There is great interest in
uncovering the processes and underlying factors that lead to
renal fibrosis in order to prevent or reverse renal fibrosis.
(17). However, it is uncertain whether the elimination of
fibrosis will in itself be sufficient to improve renal function,
while beyond this, it is also necessary to eliminate
inflammation and fibrogenesis, followed by the regeneration
and reconstruction of tissue (6). Kaissling and colleagues
suggest that renal fibrosis may have a curative component
or, on the other hand, that fibrotic tissue supports the
survival of healthy and partially injured nephrons (16).
Impact of Renal Fibrosis on Human Health
In recent years, the incidence of CKD has grown in a
frightening way. If this tendency persists, even wealthier
countries will not be able to come up with sufficient
resources to adequately treat this disease (18). Although it is
recognized that the kidney has a capacity for regeneration
after acute injury, regeneration and recovery, following
chronic injury this is much more difficult. Thus this process
is often irreversible, leading to end-stage renal collapse, a
situation that requires dialysis or renal transplantation (6). In
general, between 30-40% of individuals develop
considerable kidney failure 10-15 years after the diagnosis
of progressive nephropathy (19). It is estimated that currently
between 1 and 2 million people are being treated with renal
replacement therapy (19-21), which primarily involves
kidney transplantation and haemodialysis. Over 90% of these
patients live in developed countries, although the availability
of renal replacement therapy in developing countries is
limited, and insignificant or non-existent in underdeveloped
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countries. Given the fact that renal replacement therapy
represents a high cost burden on national health budgets, this
prevents all patients from being given access to this type of
treatment (19). The latest estimate, based on results from the
US Census Bureau predicted that by the year 2015 the
number of cases on renal replacement therapy will be
>595,000 (22). The public cost necessary to care for these
patients will be considerably greater than it was in 2010 ($28
billion per year), regardless of the exact number of cases (18,
22). If these numbers were to be estimated for the entire
world’s population, the total number of individuals with
CKD could be estimated to be in the hundreds of millions.
Humans and animals develop glomerulosclerosis, interstitial
fibrosis, tubular atrophy and reduction in glomerular filtration
rate with increasing age (23). In humans with CKD, the
development of glomerulosclerosis is evidenced by the
progressive involvement of segments within individual
glomeruli, a decrease in the total number of glomeruli and by
the simplification and elimination of tubular structures (15).
The presence of fibrosis in CKD is strongly related to the
future manifestation of renal failure and has thus been related
with poor long-term prognosis (24). Renal fibrosis is one of
the consequences of kidney injury and is associated with renal
dysfunction that may culminate in renal collapse (25, 26).
Renal fibrosis, particularly associated with glomerulosclerosis
and renal interstitial fibrosis (5, 10, 27, 28) that is
characterised by tubular atrophy, tubular dilatation, increased
fibrogenesis (29) and deposition of collagen and ECM (15),
can progress in humans as a consequence of chronic infection,
obstruction of the ureters, hypertension, diabetic nephropathy
and chronic exposure to heavy metals (25).
Principal Molecules, Cells and Other Factors
Involved in the Pathogenesis of Renal Fibrosis
In the following section we describe the main molecules and
cells that are associated with progression of renal fibrosis
and their activity in the biological process of renal fibrotic
development, such as Ang II, TGFβ, connective tissue
growth factor (CTGF), plasminogen activator inhibitor-1
(PAI1), nuclear factor-ĸB (NFĸB), fibroblasts, and proteins
(Figure 1).
Angiotensin II
All the components of the renin–angiotensin system
(including enzymes and receptors) are present in the kidney,
and renal Ang II is approximately one thousand-fold greater
than the circulating concentrations of Ang II (15). Therefore,
increased levels of Ang II modulate fibrosis by the direct
effects on the matrix and by up-regulating the expression of
other factors, such as TGFβ (5, 14), platelet-derived growth
factor (5) (which plays a crucial role in the development of
mesangial proliferation) (10), CTGF (30), nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity
(2), PAI1 (19), tumour necrosis factor-α, osteopontin,
vascular cell adhesion molecule-1, and NFĸB (NFĸB
activation is also strongly associated with an increase in
renal fibrosis) (15, 31). Ang II also induces oxidative stress.
It is believed that most of these negative effects of Ang II
are mediated by the Ang II type-1 (AT1) receptor. These
factors and the vasoactive compounds involved in the
progression of renal fibrosis have been studied in various
models of renal diseases (15).
Cell growth after injury is frequently followed by
increased apoptosis. Apoptosis may be induced by Ang II
and this effect is mediated by the Ang II type-2 (AT2)
receptor, showing a possible role for AT2 receptors in the
regression of renal fibrosis. This is demonstrated by the
activity of the AT2 receptor in the reduction of vascular
lesions after damage. In addition, regression of
glomerulosclerosis can be achieved by angiotensin inhibition
in animal studies, however, this can become more effective
when used in combination with an aldosterone antagonism
(5) or with TGFβ blockers (20). Renin and aldosterone
appear to have fibrogenic effects regardless of Ang II
activity, however, it is not known if aldosterone and renin
up-regulate TGFβ expression (32), or whether they may be
intimately connected with TGFβ production and
accumulation of fibrotic matrix.
Transforming Growth Factor β
The accumulation of ECM proteins, which is associated with
the progression of glomerulosclerosis/renal interstitial fibrosis
and tissue inflammation, seems to be related mainly with the
activity of Ang II and TGFβ (20, 32, 33). TGFβ is secreted in
an inactive (latent) form that requires processing before it can
exert its effect and latent TGFβ is stored on the surface of cells
and the ECM, where it is transformed to active TGFβ (15).
Along these lines, Kagami et al. showed that Ang II induces
ECM synthesis and that these effects are mediated directly by
Ang II induction of the active form of TGFβ (12), indicating
that TGFβ contributes to renal fibrosis (2, 12, 20, 31, 32). In
mammals there are three TGFβ isoforms, however, the form
most associated with renal fibrosis is TGFβ1 (34). TGFβ1 is
extensively expressed in all cells of the kidney, particularly in
glomeruli, where the levels are several times those in the
kidney as a whole (20), or expressed by macrophages that
invade the kidney (15). TGFβ plays a pivotal role in renal
fibrogenesis (7, 11, 20, 35), indeed the kidney is particularly
susceptible to the overexpression of TGFβ (32).
TGFβ simultaneously regulates cellular proliferation,
differentiation and migration, modulation of the immune
response (7), fibroblast proliferation (15), stimulation of
oxidative stress (increasing NADPH oxidase activity in
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mesangial cells) (2), synthesis of ECM, inhibits the activities
of proteases that degrade the matrix, and increases the
expression of cell-surface integrins that interact with matrix
components, causing an extremely high deposition of ECM
(32). In this sense, TGFβ induces ECM by stimulating the
production of matrix proteins, reducing the production of
ECM-degrading proteinases and up-regulating the production
of proteinase inhibitors, and induces glomerular mesangial
and epithelial cells (in vitro) to produce collagens,
fibronectin, proteoglycans (20), laminin (2) and endothelin
(15). Another important factor is the ability of TGFβ to
stimulate its own synthesis and activation, resulting in a self-
sustaining autocrine loop (2). On the other hand, TGFβ also
contributes to ECM through the up-regulation of PAI1 (5,
32) and increased renin release (32) in isolated glomeruli,
reducing the activity of matrix-degrading metalloproteinase
(20). This alteration to matrix degradation is also associated
with a raised expression of CTGF (2).
Connective Tissue Growth Factor
Yang et al. demonstrated that Ang II directly induces CTGF,
as well as collagen I. Ang II was found to induce CTGF
expression through a TGFβ1-independent SMAD signalling
pathway via the AT1-extracellular signal-regulated
kinase/p38 mitogen-activated protein kinase signaling
in vivo 31: 1-22 (2017)
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Figure 1. Glomerular injury can be associated with different causes, leading to endothelial dysfunction and haemodynamic changes. Activation and
amplification of many biological effects particularly with production of angiotensin II (Ang II) that up-regulates the expression of other factors,
such as transforming growth factor-β (TGFβ), connective tissue growth factor (CTGF), plasminogen activator inhibitor-1 (PAI1) and nuclear factor-
ĸB (NFĸB), leading to initial recruitment of neutrophils which is substituted by macrophages and T-lymphocytes, triggering an immune response,
causing interstitial nephritis. Tubular cells respond to this inflammatory process by forming a lesion of the basal membrane and by epithelial–
mesenchymal transition transformed into interstitial fibroblasts. The formed fibroblasts produce collagen, and result in an imbalance between
excessive synthesis and decreased breakdown of the extracellular matrix, which in turn damages the blood vessels and the kidney tubules, with the
possibility of forming of a cellular scar and consequently renal fibrosis. RAAS: Renin–angiotensin–aldosterone system.
pathway to induce renal fibrosis in tubular epithelial cells
(30). On the other hand, induction of CTGF by TGFβ1 is
markedly inhibited by SMAD7 overexpression (30, 36). In
another study, in vivo results showed that Ang II directly
activates the SMAD pathway in the vessel wall and regulates
numerous SMAD-dependent proteins implicated in vascular
fibrosis, by a direct TGFβ independent mechanism (37). This
demonstrates the crucial function of SMAD signalling in the
Ang II-mediated fibrotic process (30). The RAS/MEK/
ERK1/2 signaling pathway is also required for the
stimulation of CTGF by TGFβ1 in human proximal tubular
epithelial cells, and among the RAS isoforms that are
expressed in human kidney cells, NRAS but not KRAS or
HRAS were required for the induction of CTGF by TGFβ1
(36). CTGF also appears to be correlated with the degree of
tubulointerstitial fibrosis in experimental and human renal
fibrosis studies (11). Indeed, CTGF is most abundant in the
kidney compared to other tissues, and is an important
mediator of renal fibrosis. In a way, there is real potential for
CTGF to become a therapeutic target for the treatment of
renal fibrosis. CTGF and TGFβ act jointly to promote
chronic fibrosis (11, 36).
Plasminogen Activator Inhibitor-1
PAI1 is another mediator that is associated with increased
renal fibrosis (19), by stimulation of fibronectin and type III
collagen (15). Ang II may also promote PAI1 directly, both
in vitro and in vivo (5), which may lead to an accumulation
of ECM by reducing the activities of plasmin in eliminating
the matrix and stimulating collagenases (32). This shows that
the Ang II blockade is extremely important in combatting the
evolution of renal fibrosis.
Nuclear Factor-ĸB
NFĸB has a role in the transcriptional regulation of a
quantity of genes in different tissues, namely the renal cells
(38). NFĸB is located in the cell cytoplasm in an inactive
form, linked to an inhibitor, the activated form of NFĸB is a
homodimer or heterodimer, structured by two proteins that
are part of the NFĸB family. In this sense, transcription
factors of the NFĸB family can stimulate cells, directly or
indirectly, triggering tissue fibrosis (15). Ang II can be
activated by NFĸB through both the AT1 and AT2 receptors.
The NFĸB family of transcription factors have several
potential associations, it is probable that different NFĸB
isotypes are stimulated by Ang II at different phases in the
progression of renal disease (31). The tissue enzyme
transglutaminase (protein expressed by kidney tubular
epithelial cells) is an activator of latent TGFβ1 and the
activating of transglutaminase is regulated by NFĸB,
consequently this fact appears to be associated with an
increase of renal fibrosis. The increased expression of a-
smooth muscle actin promotes the kidney fibroblasts to
achieve a myofibroblastic phenotype (15). It appears that
NFĸB may be associated with an increase in α-smooth
muscle actin expression during liver fibrosis (39). As
mentioned above, Ang II can promote NFĸB activation,
activating tumour necrosis factor-α synthesis; this in turn can
additionally activate NFĸB. A 40% reduction in tumour
necrosis factor-α mRNA expression was verified with
angiotensin-converting enzyme inhibition in rats with kidney
disease, perhaps due to the weakening of a group of NFĸB
homodimers or heterodimers (31). Therefore, the progression
of renal fibrosis might be treated or improved by inhibition
of NFĸB (15, 38, 40).
Fibroblasts
The progression of renal fibrosis is a complex process, since
many factors and cells are involved, especially mesenchymal
cells (6). Epithelial–mesenchymal transition, a process by
which differentiated epithelial cells give rise to the matrix-
producing fibroblasts and myofibroblasts, is increasingly
documented as an integral part of tissue fibrogenesis after
renal injury (13, 35, 41). In this sense, tubular epithelial cells
are also important in the pathogenesis of tubulointerstitial
fibrosis (29). Thus, epithelial–mesenchymal transition, such
as occurs in common glomerular diseases, could be a
primary pathway leading to podocyte dysfunction,
proteinuria, and glomerulosclerosis (13). Fibroblasts are
mesenchymal cells involved in the progression of renal
disease. Fibroblasts of the renal interstitium can play a
contractile myofibroblastic phenotype and has the ability to
originate fibrillar collagen-rich ECM, leading to impaired
renal function. The number of fibroblasts increase during
renal disease and can be activated by many cytokines,
especially TGFβ1 or differentiate into myofibroblasts (34).
Proteins
Another strategy for preventing, or at least slowing, the onset
of glomerulosclerosis is a low-protein diet because a high
protein intake increases the glomerular filtration rate by
reducing afferent arteriolar resistance and consequently
increasing glomerular capillary pressure (2). Elevated levels
of urinary proteins, which correspond to excess protein
passage through the glomerulus, are related to a quicker
progression of renal disease (20). Thus, proteinuria is also
an important factor of progression in animal and human renal
diseases. One of the factors that causes glomerular and
tubular changes includes enhanced glomerular capillary
pressure by altering glomerular permeability to proteins,
allowing proteins to pass across the glomerular filter and
reach the lumen of the proximal tubule. Another factor of
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tubular reabsorption of filtered proteins that contributes to
interstitial damage is by activating intracellular events,
leading to up-regulation of the genes encoding vasoactive
and inflammatory mediators (20).
Animal Models of Renal Fibrosis
Experimental models are widely used to study the
mechanisms involved in the progression of renal diseases to
renal fibrosis (5, 7). Research on natural aging of the rat
kidneys indicate that both gender and genetic background
influence the rate, as well as the level, of impairment and
scarring from renal disease. Normally, age-related renal
scarring begins earlier and becomes more severe in male rats
than in females, and Sprague-Dawley rats are less resistant
than other rat strains. Research into aging in mice suggests
that strain and gender also influence the progression of renal
disease (23). It is important to emphasize that these changes
are clearly different from the compensatory changes that
occur after reduction of renal mass (42). To study renal
fibrosis, induced models (surgical and chemical),
spontaneous models, genetic models and in vitro models (29,
43-48) can be used.
Chemical Models of Renal Fibrosis
There are several chemical models for studying renal
fibrosis, each of which has advantages and disadvantages.
We describe each of them below in turn, while in Table I, the
practical application of each of these models in the
therapeutic evaluation of different drugs is presented.
Mercuric chloride (HgCl2). HgCl2 per os in Sprague-Dawley
rats once a day for 9 weeks led to renal interstitial fibrosis
with an increased amount of collagen. The effect of HgCl2
is characterized by the activation of renal fibroblasts, the
overproduction and deposition of ECM, increased renal lipid
peroxidation (49), elevated NFĸB activity (50), renal
necrosis and tubular dysfunction in rats (51).
Vanadate. Vanadate injected subcutaneously in Sprague-
Dawley rats aged 11 weeks at a dosage of 0.9 mg/kg per day
for 16 days caused inflammation and renal fibrosis. The
pathological and biochemical changes were more severe in
the kidney tissue. After 2 days, degenerative and necrotic
changes of the tubular and glomerular epithelium were
identified. After 12 days, cellular proliferation in both the
cortex and medulla was significantly greater and there was
verifiable renal fibrosis: glomerular tuft, preglomeruli,
pretubules and interstitium (cortex and medulla). After 25
days, collagen deposition reached the highest degree in all
areas of the kidney. Vanadium-produced fibrosis in tissues is
dose-dependent (52).
Adriamycin. Adriamycin is an antineoplastic drug that induces
side-effects such as lipid peroxidation in glomerular epithelial
cells. Adriamycin induced rat nephropathy with massive
proteinuria, tubular basement membrane lesions, probably
causing an inflammatory response and interstitial fibrosis (4).
Adriamycin administration at a dosage of 10 mg/kg for each
mouse by means of a single intravenous tail-vein injection
causes proteinuria, glomerular and podocyte injury, followed
by tubular atrophy and finally renal fibrosis (53-55). In a study
with BALB/c mice, proteinuria was verified on day 5 and at
higher levels on day 7; after weeks 1 and 2 glomerular and
tubular lesions were observed, and by week 4 these changes
were more evident. After week 6, kidney inflammation was
observed, as well as severe glomerulosclerosis and interstitial
fibrosis (53). The adriamycin-induced nephropathy model
mimics human disease of focal segmental glomerulosclerosis
(54) and is also often used to model nephrotic syndrome (23).
This model is also excellent for investigating
glomerulosclerosis in humans (23).
Uranyl nitrate. Uranyl nitrate administrated by intraperitoneal
route (0.3 or 0.5 mg/100g) causes renal fibrotic changes in
rats. Uranyl nitrate administration induced mild to moderate
patchy interstitial fibrosis after 4 weeks. After 20 weeks,
fibrotic areas containing atrophic tubules with a thickened
tubular basement membrane and mild lymphocytic infiltration
were identified. Uranyl nitrate administration induced renal
fibrosis in a dose-dependent manner (29). In another study,
uranyl nitrate administration of 10 mg/kg in rats for a period
of 2 months appeared to cause chronic injuries, as
demonstrated by increased interstitial fibrosis, atrophic
proximal tubules and mononuclear cell infiltrates. These
authors suggest that the administration of uranyl nitrate in rats
induced renal failure with a slow recovery phase and long-
term pathological lesions (56). Uranyl nitrate appears to be
an optimal model of interstitial fibrosis and is useful for
investigating molecular mediators of kidney damage (29).
Folic acid. Folic acid administered via the intraperitoneal
route (240 mg/kg) in mice induced the rapid appearance of
folic acid crystals in tubules, followed by severe
nephrotoxicity, between 1-14 days of the administration
period. By 28-42 days, these animals developed patchy
interstitial fibrosis. Severe damage induced by folic acid is
associated with a direct toxic effect on tubular epithelial cells
and by crystal obstruction of individual tubules. However, the
co-administration of NaHCO3 and folic acid provokes urine
alkalinisation, reducing crystal formation (23, 57). The folic
acid interstitial fibrosis model, compared to the unilateral
ureteral obstruction (UUO) model, has the advantage of
enabling assessment of renal function as a measure of CKD.
On the other hand, this model has the limitation of being
somewhat variable and the possibility exists that fibrosis in
in vivo 31: 1-22 (2017)
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some mice will regress spontaneously after 42 days. This
model is good for studying interstitial fibrosis (23).
Streptozotocin-diabetic rats. Streptozotocin administration
(65 mg/kg i.v.) in rats increases blood glucose concentration.
After 4 or 8 weeks of streptozotocin administration, animals
showed collagen deposition in the kidneys, elevated renal
plasma fibronectin concentrations (58) and elevated plasma
levels of TGFβ, up to four times the normal levels (14). This
model can be considered as a renal fibrosis model because
sometimes, after the onset of diabetes, renal fibrosis may
occur (58).
Cyclosporine A. Cyclosporine A, a primary calcineurin
inhibitor, is used clinically as an immunosuppressive agent
to enhance the efficacy of organ transplantation. However,
prolonged use of cyclosporine A can induce renal fibrosis.
Thus, its clinical use is in part limited by its nephrotoxicity
effect (3, 59). The cyclosporine A model is good for studying
interstitial fibrosis (23). However, this model has some
disadvantages: high cost, liver toxicity, extensive trial period
(4) and the concentrations of cyclosporine A that are
commonly used in animal studies are much higher than those
used in clinical practice (60).
Physical Models - Radiation Nephropathy
Radiation nephropathy can be induced by a local dose 
(10 Gy), with shielding of the gastrointestinal tract and
without systemic toxicities. Radiation nephropathy leads to
the development of endothelial injury and chronic
progressive secondary sclerosis with proportional
tubulointerstitial fibrosis (23). In Sprague-Dawley rats,
radiation (12 Gy) induces an initial decline in glomerular
filtration rate and at a later stage, the damage involves
complex interactions between glomerular, tubular and
interstitial cells, which may culminate in interstitial fibrosis
with mild interstitial inflammation. In addition to the likely
involvement of TGFβ and PAI1, Ang II is certainly the
principal mediator of this process. The results of this study
showed that sulodexide (15 mg/kg/day by subcutaneous
injection, 6 days/week for 4, 8 and 12 weeks) is effective in
reducing the early, but not late, indicators of radiation
nephropathy and has no influence on renal damage, despite
sulodexide considerably diminishing TGFβ activation (61).
Surgical Models to Induce Renal Fibrosis
There are three main surgical models to study renal fibrosis,
each of which has its advantages and disadvantages. We
describe each of them below, and Table II shows the
practical application of each of these models in the
therapeutic evaluation of different drugs.
5/6 Renal mass reduction. Over the last 50 years, models
using animals that have undergone surgical renal reduction
have been used to study progressive renal disorders (17, 62).
The remnant kidney model of progressive renal disease has
been used in different rat and mouse strains to study the
pathogenesis of glomerulosclerosis. The 5/6 renal mass
reduction model in rats is frequently studied to evaluate
alterations in the progression of chronic kidney failure,
namely renal fibrosis (5, 7, 63). A study conducted by
Hostetter and colleagues highlighted the action of glomerular
hyperfiltration in the development of lesions in remnant
glomeruli in rats (64). However, Ma and Fogo, in a study
that used the remnant kidney model, recorded small
glomerular changes in C57BL/6 mice. On the other hand, in
129/Sv and Swiss-Webster strains, mice were observed to
have significant glomerular sclerosis, so to some extent these
results demonstrate the effect of genetic background on renal
response to renal reduction (65). Sensitivity to the
development of glomerulosclerosis and hypertension in
129/Sv and C57BL/6 strains may be predisposed by renin
gene polymorphisms. Mice with two renin genes have 10-
times greater renin activity in their plasma compared with
mice with one renin gene. Because of this increased renin
activity in 129/Sv mice, they exhibit a greater predisposition
for developing hypertension and glomerulosclerosis (66).
Although research studies focus on the various processes of
kidney function, clinical studies have also established that
the development of renal failure correlates more with renal
interstitial fibrosis than with glomerular injury (17).
In the 5/6 renal mass reduction animal model, a renal
mass reduction of >85% is required to simulate the decrease
in the number of nephrons that occurs with CKD, which
makes this model an excellent model for studying the
mechanisms involved in compensatory adaptations to
nephron loss. The 5/6 renal mass reduction model is
achieved by unilateral nephrectomy, followed by the
removal of two-thirds of the remaining kidney (67, 68). For
the study of renal disease, this can be performed in one of
two ways: a) unilateral nephrectomy plus polectomy of the
remnant kidney, resulting in approximately 5/6 renal mass
reduction; and b) unilateral nephrectomy plus complete
ligation of two branches of the contralateral renal artery,
resulting in infarction of approximately 2/3 of the remnant
kidney, which produces an overall 5/6 renal mass
nullification (1). In the 5/6 renal mass reduction model, the
remaining nephrons increase their filtration rate (64) to
preserve the excretory function; renal dysfunction occurs
when the remaining nephrons are unable to perform this
excretory function (1). Over time, these animals develop a
syndrome of systemic and glomerular hypertension (68),
proteinuria (64) and matrix expansion (5), and by 12 weeks
present progressive glomerulosclerosis and tubulointerstitial
fibrosis in the originally healthy remnant nephrons (23, 62,
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Table I. Chemical models used for renal fibrosis study - drugs evaluated and their efficacy.
Drug-induced      Strain/gender/                            Protocol                                             Drugs and                                    Results and therapeutic
models                    age, weight                                                                                compounds evaluated                                effects (reference)
HgCl2                 Sprague-Dawley/             8 mg HgCl2/kg/day p.o.                Fuzheng Huayu formula and                Fuzheng Huayu formula and  
                               ♂/120±10g                   for 9 weeks to induce                vitamin E by oral gavage (4.0 g               Vitamin E demonstrated an 
                                                                    renal interstitial fibrosis            crude drug/kg/day and 100 mg/kg/               inhibitory effect on renal 
                                                                                                                           day, respectively) for 9 weeks              fibrosis induced by HgCl2 (49)
                        Sprague-Dawley/♂/       8 mg HgCl2/kg/day p.o. for                100 mg Vitamin E/kg/day                    Vitamin E shown to inhibit 
                                  120±10g                    9 weeks to induce renal                by gastric gavage for 9 weeks                    renal interstitial fibrosis 
                                                                        interstitial fibrosis                                                                                           induced by HgCl2 (50)
                          Wistar/♂/8 weeks           2.5 μmol HgCl2/kg/2 ml                                        -                                       Renal function is significantly 
                             and 20 months              i.v. for 4 weeks to induce                                                                          compromised in aged rats, resulting 
                                                                    renal interstitial fibrosis                                                                             in chronic renal insufficiency, and 
                                                                                                                                                                                       the accumulation of HgCl2 in aging 
                                                                                                                                                                                              rats is significantly altered 
                                                                                                                                                                                       compared to that of young rats (51)
Vanadate            Sprague-Dawley/        1 mg Vanadate/kg/day s.c. for             500 mg Pirfenidone/kg/day                       Pirfenidone treatment 
                                ♂/9 weeks        12 days to induce mild to moderate               by oral gavage for                          decreases vanadate-induced 
                                                        kidney lesions and the same treatment             23, 37 and 41 days                                  renal fibrosis (25)
                                                              protocol for 16 days to induce 
                                                           moderate to severe kidney lesions
                          Sprague-Dawley/      0.9 mg Vanadate/kg/day s.c. for                                 -                                         Vanadate treatment induced 
                               ♂/11 weeks            16 days to evaluate the effects                                                                                     renal fibrosis in a 
                                                                 of vanadate on renal tissue                                                                                dose-dependent manner (52)
Adriamycin            BALB/c/♂/          A single administration of 10 mg      Atrasentan by i.p., two different             Atrasentan was ineffective in 
                              6 to 8 weeks          adriamycin/kg i.v., urine, blood       protocols: 1: prevention protocol                  improving renal injury 
                                                          and kidney samples were collected     (5 mg/kg; daily starting the day               associated with adriamycin-
                                                             on the day of sacrifice (1, 3, or         prior to adriamycin injection);                  induced nephropathy (54)
                                                          5 weeks after adriamycin injection)       2: therapeutic protocol (7 and 
                                                                                                                           20 mg/kg) three times weekly                                        
                               BALB/c/♂/          A single administration of 10 mg      Mas receptor agonist-AVE0991            AVE0991 had a renoprotective 
                             8 to 10 weeks      adriamycin/kg i.v., urine, blood and    and Losartan (3 mg/kg p.o. and              effect on adriamycin-induced 
                                                              kidney samples were collected           10 mg/kg p.o., respectively)               nephropathy, these effects were 
                                                                 (0, 7, 14 and 21 days after                from day 7 to day 14 after                   similar to those of losartan. 
                                                                      adriamycin injection)                          adriamycin injection                      AVE0991 and losartan reduced 
                                                                                                                                                                                           histological injury indices (55)
                               BALB/c/♂/           A single administration of 10 to                                 -                                         The results showed that the 
                             8 to 10 weeks         11 mg adriamycin/kg i.v., urine,                                                                          model of adriamycin-induced 
                                                             blood and kidney samples were                                                                       nephropathy may be useful in the 
                                                              collected (1, 2, 4 and 6 weeks                                                                               study of the pathogenesis 
                                                                 after adriamycin injection)                                                                               of renal fibrosis in CKD (53)
Uranyl nitrate          Wistar/♀/               0.3 or 0.5 mg Uranyl nitrate/                                    -                                        After 4 weeks, 0.5 mg uranyl 
                                 150-170g              100g by only one i.p., diuresis                                                                          nitrate administration caused a 
                                                           experiments were performed 2, 4,                                                                   mild to moderate patchy interstitial 
                                                                8, 10, 20 weeks after uranyl                                                                        fibrosis, after 0.3 mg uranyl nitrate 
                                                                      nitrate administration                                                                                administration, renal fibrosis was 
                                                                                                                                                                                                 milder, after 20 weeks, 
                                                                                                                                                                                       administration of uranyl nitrate had 
                                                                                                                                                                                               induced renal fibrosis (29)
                          Sprague-Dawley/   10 mg Uranyl nitrate/kg by a single                              -                                      Administration of uranyl nitrate 
                               ♂/250-300g           s.c., renal function studies and                                                                         appears to have caused chronic
                                                              morphological evaluation were                                                                       lesions, since an increase in renal 
                                                              performed 1, 2, 4 and 8 weeks                                                                          fibrosis, particularly interstitial
                                                                   after drug administration                                                                                     fibrosis (56), was found
Folic acid            CD1/♂/8 weeks                240 mg Folic acid/kg                                          -                                          After 14 days of folic acid 
                                                                      by i.p., kidneys were                                                                                  administration, cortical tubular 
                                                                     harvested at 0.5, 1, 3,                                                                                        atrophy and interstitial 
                                                                        7, and 14 days for                                                                                       fibrosis (57) were observed
                                                                     histological evaluation
Table I. Continued
68). In this model, the alterations to the matrix metabolic
enzymes in the remnant kidney strengthen the idea that an
imbalance of matrix generation/degradation may contribute
to the development of renal damage and renal fibrosis
following 5/6 renal mass ablation (9). Regardless of
aetiology, the reduction in functioning renal mass is
associated with progressive glomerulosclerosis (67). This
fact makes the 5/6 nephrectomy model one of the most
often-used in the study of glomerulosclerosis. However, this
model is limited due to the difficulty of performing surgery,
the high mortality rate and the sudden loss of a large amount
of renal tissue that occurs very rarely in human disease,
where loss of functional renal tissue typically occurs more
gradually.
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Table I. Continued
Drug-induced      Strain/gender/                            Protocol                                             Drugs and                                    Results and therapeutic
models                    age, weight                                                                                compounds evaluated                                effects (reference)
Streptozotocin         Wistar/♂/                A single injection of 65 mg           Pirfenidone and spironolactone            Pirfenidone and spironolactone 
                               8-10 weeks                   streptozotocin/kg i.v.,                after 4 weeks, were given either           treatment reduced renal fibrosis 
                                                                experiments were performed           200 mg pirfenidone/l drinking           in the rat model of streptozotocin 
                                                                        4 or 8 weeks after                   water; or 50 mg spironolactone/                          treatment (58)
                                                                   streptozotocin treatment              kg/day s.c. for a further 4 weeks                                      
Cyclosporine A Sprague-Dawley/        25 mg Cyclosporine A/kg/day                                   -                                       Cyclosporine A administration 
                               ♂/180-230g               by oral gavage for 21 days                                                                            altered the proximal convoluted 
                                                                     (but without salt diet),                                                                                 tubules and glomeruli showed 
                                                              measurements were performed                                                                             significant damage to their 
                                                                    at the beginning and at                                                                                       structural integrity (3)
                                                                 the end of treatment period
                        Sprague-Dawley/♂/      20 mg Cyclosporine A/kg/day                                   -                                        Results revealed significantly 
                                 220-250g              by gastric gavage for 35 days                                                                         augmented expression of TGFβ1 
                                                            (after 1 week on a low salt diet),                                                                       in renal tubular cells induced by 
                                                              measurements were performed                                                                                chronic cyclosporine A 
                                                               at the end of treatment period                                                                                     administration (45)
                        Sprague-Dawley/♂/      15 mg Cyclosporine A/kg/day       Eplerenone administration-tablets        Eplerenone administration showed
                                180g-240g           by a daily gavage for 12 weeks,        of 50 mg by p.o., 1,2 mg/g dry                 a preventive effect in the 
                                                              measurements were performed        food approximating a daily dose         development of renal fibrosis (59)
                                                               at the end of treatment period              of 100 mg/kg body weight                                           
                        Sprague-Dawley/♂/      15 mg Cyclosporine A/kg/day               80 mg Tea polyphenols/                    Tea polyphenol administration 
                                 200-230g                    by gavage for 28 days                kg/day by gavage after 1 week            reduced TGFβ1 expression and 
                                                              (after 1 week on low salt diet),                      on low salt diet                             renal fibrosis in a rat model 
                                                              measurements were performed                                                                                of chronic cyclosporine 
                                                               at the end of treatment period                                                                                  A administration (103)
                          Sprague-Dawley/          Three distinct studies were               0,3 mg Sirolimus/kg/day by           Early conversion from cyclosporine 
                               ♂/230-250g           performed (15 mg cyclosporine              a daily s.c. according to                   A to sirolimus was effective in 
                                                                  A/kg/day by a daily s.c.):                      the study performed                          inhibiting cyclosporine A-
                                                              1: cyclosporine A for 4 weeks;                                                                             induced renal damage (60)
                                                           2: cyclosporine A for 1 week, and 
                                                                 then replaced by sirolimus 
                                                          (early conversion); 3: cyclosporine 
                                                            A for 4 weeks and then replaced 
                                                                   by sirolimus for 4 weeks 
                                                            (late conversion). Measurements 
                                                                     were performed at the 
                                                                    end of treatment period
                           ICR/♂/9 weeks/           Animals were treated with                                     -                                    Data demonstrated that the NRF2
                              with Nrf2+/+              either olive oil (5 ml/kg)                                                                            –heme oxygenase-1 system has a 
                                or Nrf2−/−                   or olive oil-suspended                                                                             protective role against cyclosporine
                                 genotype              cyclosporine A (30 mg/kg) by                                                                              A-induced renal fibrosis by 
                                                               gavage for 2 weeks, samples                                                                                  modulating epithelial–
                                                             (blood and kidneys) were taken                                                                               mesenchymal transition 
                                                               at the end of treatment period                                                                                      gene changes (97)
i.v.: Intravenous; s.c.: subcutaneous; i.p.: intraperitoneal; p.o.: per os; HgCl2: mercuric chloride; CKD: chronic kidney disease; TGFβ: transforming
growth factor β; NRF2: nuclear factor E2-related factor 2.
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Table II. Surgical models used for renal fibrosis study – drugs evaluated and their efficacy.
Surgical induction    Strain/gender/                            Protocol                                             Drugs and                                   Results and therapeutic 
method                        age, weight                                                                              compounds evaluated                               effects (reference)
5/6 Renal mass     Sprague-Dawley/          In the first step, two poles               Mycophenolate mofetil and                 Mycophenolate mofetil and
reduction (two           ♂/280-300g                 of the left kidney were                   benazepril by oral gavage               benazepril alone, and especially 
surgical times)                                           removed and one week later       (20 mg/kg/day/for 8 weeks; 10 mg/                  combined, improve 
                                                                  the right kidney was removed        kg/day/for 8 weeks, respectively)             tubulointerstitial fibrosis (9)
                                     Wistar/♀/                     In the first step, two                                          -                                         Did not cause any fibrotic 
                                     150-170g                   poles of the left kidney                                                                              alterations during the 20-week 
                                                                  were removed and three days                                                                                    study period (29)
                                                                     later the right kidney was 
                                                                 removed. Diuresis experiments 
                                                                 were performed 1, 4, 8, 10, 20 
                                                                   weeks after 5/6 nephrectomy
                               Sprague-Dawley/          In the first step, two poles                Vitamin E by oral gavage                        Long-term vitamin E 
                                   ♂/12 weeks                 of the left kidney were                    5,000 IU α-tocopherol/kg                       therapy reduced renal 
                                                                   removed and one week later                    chow for 15 weeks                                      fibrosis (95)
                                                                  the right kidney was removed
5/6 Renal mass           Wistar/♂/                    5/6 Nephrectomy was                                         -                                          Endoglin expression was
reduction (one               ≈ 250g                    performed by ligation of                                                                                     increased in rats with 
surgical time with                                        two or three branches of                                                                                         renal fibrosis (7)
artery ligation)                                               the left renal artery and 
                                                                           right nephrectomy
                                     Wistar/♂/                    5/6 Nephrectomy was                  0.2 mg Halofugione/kg/day                      Halofuginone reduced 
                                      300±10g                  performed by ligation of                 by oral gavage for 8 weeks                          renal fibrosis (89)
                                                                   two of three branches of the 
                                                                          left renal artery and 
                                                                           right nephrectomy
5/6 Renal mass     Sprague-Dawley/             5/6 Nephrectomy was                    Rehmannia glutinosa p.o.                 Rehmannia glutinosa reduced
reduction (one           ♂/250-300g                performed by removing               administration of the aqueous                  renal fibrosis principally 
surgical time)                                                  the whole right kidney                      extract 500 mg/kg/day                     by inhibiting the expression 
                                                                    and upper and lower poles                            for 8 weeks                              of Ang II and AT1 receptors, 
                                                                            of the left kidney                                                                                 TGFβ1, and type IV collagen (43)
                                             
                               Sprague-Dawley/             5/6 Nephrectomy was                Animals received gene therapy             Ang II induces renal fibrosis
                            ♂/6 weeks/220-250g         performed by removing                 with doxycycline-inducible                  via the TGFβ by a SMAD 
                                                                    the whole right kidney and                 Smad7 or empty vectors                       signalling pathway (30)
                                                                        upper and lower poles                  mediated by an ultrasound-
                                                                            of the left kidney                           microbubble technique                                             
5/6 Renal mass        C56BL/6/♂/,           The lower branch of the left                                   -                                      Genetic background is one of 
reduction                     129/Sv/♂,                 renal artery was ligated                                                                                  the significant factors that 
(modified                Swiss-Webster/           to produce about one third                                                                              determines a predisposition 
surgical                  ♂/8 to 10 weeks              area with visible renal                                                                                       to the progression of 
protocol)                                                        ischemia; the upper pole                                                                                       glomerulosclerosis 
                                                                        of the left kidney was                                                                                              in mice (65)
                                                                      removed by cautery and 
                                                                          the right kidney was 
                                                                     nephrectomized to induce 
                                                                      a total 5/6 nephrectomy. 
                                                                   In some C57BL/6 mice, 7/8 
                                                                     nephrectomy was induced 
                                                                  by removing additional renal 
                                                                   mass from the upper pole of 
                                                                     the left kidney by cautery
5/6 Renal mass     Sprague-Dawley/          Renal mass reduction was                Fasudil + aldosterone s.c.,              Fasudil significantly diminished
reduction (one           ♂/182-206g            performed, with the removal              after 2 weeks of recovery                         aldosterone-induced 
surgical time                                                of the right kidney alone                    from surgery, rats were                             renal fibrosis (93)
with the removal                                                                                                     treated for 5 weeks with: 
of the right                                                                                                             (1) Vehicle; (2) aldosterone 
kidney alone)                                                                                                           (0.75 μg/h); aldosterone + 
                                                                                                                                    fasudil (10 mg/kg/day)                                            
Table II. Continued
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Table II. Continued
Surgical induction    Strain/gender/                            Protocol                                             Drugs and                                   Results and therapeutic 
method                        age, weight                                                                              compounds evaluated                               effects (reference)
UUO                      Sprague-Dawley/            UUO was performed by                Losartan in drinking water 1              Ang II blockade with losartan 
                                   ♂/450-500g                         left unilateral                      day before UUO and continued                  considerably decreased 
                                                                             ureteral ligation                        daily until the animals were                  renal injury, and improved 
                                                                                                                            sacrificed on day 21 (250 mg/l)                      renal fibrosis (76)
                             B1+/+ and B1–/–/♂;            UUO was performed                  Kinin B1 receptor antagonist                Kinin B1 receptor blockade 
                                   C57BL/6/♂/                      by left unilateral                         by oral gavage in aqueous                    reduced the development 
                                   8-12 weeks                       ureteral ligation                   solution 1 day before obstruction                  of renal fibrosis (74)
                                                                                                                              or 3 days after and continued 
                                                                                                                          throughout the time of obstruction 
                                                                                                                                 (10 mg kinin B1 receptor 
                                                                                                                             antagonist SSR240612/kg/day)
                               Isogenic kinin 1              UUO was performed                                         -                                         Kinin B1 receptor removal 
                              receptor-deficient          by left unilateral ureteral                                                                                     may be a significant 
                                   C57BL/6/♂,                ligation. Experimental                                                                                      factor in renal fibrosis 
                            wild-type C57BL/6/         protocol was performed                                                                                          prevention (44)
                              ♂/8 weeks 25-28g                 at days 1, 5 and 
                                                                               14 after UUO
                                Adult (12 to 20               UUO was performed                                         -                                      Study of the differentiation of 
                               weeks) or young        through a left flank incision.                                                                       pericytes and into myofibroblasts 
                                (P12 – neonates           The ureter was identified                                                                                in the ureteral obstruction 
                                  12 days after               and tied at the level of                                                                               model of renal fibrosis. Renal 
                                birth) C57BL/6         the lower pole of the kidney                                                                           fibrosis research should focus 
                                   or coll-GFP              with two separate silk ties                                                                          on injury of the vasculature rather 
                                                                                                                                                                                          than injury to the epithelium (41)
                           C57BL/6 (wild-type)/          UUO was performed                                         -                                    Ang II plays a central role in the 
                              ♀/10 wk 20g-22g;        by the left ureter ligation,                                                                          development of tubulointerstitial 
                        AT1a-deficient (mutant)/      kidneys were harvested                                                                                       fibrosis via the AT1 
                            ♀/10 weeks 25g-25g            at 2, 5, and 10 days                                                                                         receptor in UUO (75)
                                                                               after UUO for 
                                                                        histological evaluation
                              TWEAK deficient             UUO was performed                                         -                                      Deletion of TWEAK reduced 
                            or wild type C57BL/       by the left ureter ligation,                                                                                     renal fibrosis by Ras 
                               6/10 to 14-weeks            kidneys were harvested                                                                                            pathway (48)
                                                                          at 48 h, 7, 14 or 21 
                                                                         days after surgery for 
                                                                           histological studies
                                   C57BL/6/♂/                  UUO was performed              0.8 mg Ang II/kg by a single i.p.;            Inhibition of RAS pathway 
                                     2 months                 by the left ureter ligation,              40 mg losartan/kg by a daily             activation may be a therapeutic 
                                                                       kidneys were harvested               i.p.; 70 mg atorvastatin/kg/day                  target in the prevention 
                                                                     according to the treatment            by oral gavage; 40 mg farnesyl                   of renal fibrosis (100)
                                                                        and group of the study             transferase inhibitor/kg s.c.; 3 mg 
                                                                                                                             chaetomellic acid A/kg/day s.c.
Ischaemia                     Wistar/♀/                  The left kidney was laid                                       -                                           Ischaemia did not cause 
                                     150-170g                  bare and the renal artery                                                                                       significant fibrotic 
                                                                  was ligated for 20 or 45 min.                                                                                 alterations during the 
                                                                    Diuresis experiments were                                                                               20-week study period (29)
                                                                       performed 8, 12, 16, 20 
                                                                        weeks after ischaemia
                                   C57BL/6/♂/                Animals were subjected                  1.5 mg Rapamycin/kg/day              Delayed treatment of rapamycin 
                              7-9 weeks 20-25g         to either 45 or 60 minutes                 s.c. starting 1 week after                  after an ischemia reperfusion
                                                                  of unilateral kidney ischemia.              surgery for up to 3 weeks                    injury had an insignificant 
                                                                     Diuresis experiments and                                                                               effect on renal fibrosis (78)
                                                                       fibrosis evaluation were 
                                                                           performed 4 weeks 
                                                                              after ischaemia
                          Adult (12 to 20 weeks)   Ischemia reperfusion injury                                    -                                        Study the differentiation of 
                               or young (P12 –           was performed through a                                                                              pericytes into myofibroblasts 
                               neonates 12 days       left flank incision. A surgical                                                                            in the ischemia-reperfusion 
                            after birth) C57BL/6      clamp was placed over the                                                                            model of renal fibrosis. Renal 
                                   or coll-GFP           artery and vein for 35 minutes                                                                      fibrosis research should focus on 
                                                                   and then removed. Return of                                                                         injury of the vasculature rather 
                                                                    blood flow was confirmed.                                                                          than injury to the epithelium (41)
s.c.: Subcutaneous; i.p.: intraperitoneal; p.o.: per os; TGFβ: transforming growth factor-β; TWEAK: tumour necrosis factor-like weak inducer of
apoptosis; Ang II: angiotensin II; AT1: angiotensin II type-1; UUO: unilateral ureteral obstruction; coll-GFP: collagen type I-α 1 transcript.
As a result of the renal mass reduction, the number of
nephrons suddenly decreases and the remaining nephrons
begin to develop renal damage, which depends on: the
surgical method used; the amount of tissue removed; the
strain and sex of the animal (67); and the experimental
technique (1). Fleck and colleagues demonstrated that male
rats are more resistant to 5/6 renal mass ablation than female
rats, and suggest higher resistance in Sprague-Dawley rats to
5/6 renal mass ablation compared with Wistar rats, indicating
that strain and gender influence the progression of renal
disease in the experimental model of a 5/6 nephrectomy (69).
Unilateral ureteral obstruction. Obstructive uropathy is the
main cause of end-stage renal disease in children of the
United States, being one of the main reasons for paediatric
kidney transplants (70). Urinary pathway obstruction, which
may result either from the blockage of one or both ureters,
provokes the progressive damage of renal structures, which
leads to chronic renal dysfunction. Ureteral obstruction leads
to kidney enlargement, caused by urine collecting in the
renal pelvis or calyces, which causes hydronephrosis (1, 71).
This situation therefore causes renal dysfunction by
impeding the normal flow of urine through the renal pelvis,
ureters, bladder and urethra (1). In rodents, UUO can be
considered the most widely used model to study the
mechanisms of non-immunological tubulointerstitial fibrosis
(72). The surgical technique applied to achieve this animal
model is relatively simple, if performed as a single process
in an adult rats (17) and mice (31), with the ligation of the
ureter being most frequentlyused technique [see Chevalier et
al. (17)]. In general, the alterations caused by this model are
established within 7 days in mice and 2-3 weeks in rats (4).
UUO is the most widely used interstitial fibrosis model,
due to the rapid tubular atrophy and interstitial fibrosis
development and matrix deposition (73). The UUO animal
model and human obstructive nephropathies have very
similar aetiology. However, this absolute obstruction very
rarely occurs in humans, but due to its accelerated time
course, this model reproduces a fibrotic sequence of events
that is almost identical to that found in humans (1, 31). In
UUO, the first alterations observed in the kidneys are
haemodynamic, mainly triggered by the increased activity
of the vasoconstrictor systems, namely the renin–
angiotensin system (72). After complete UUO in the
obstructed kidney, there is a progressive decline in renal
blood flow, glomerular filtration rate and rapid damage of
the renal parenchyma. Most of the renal cellular alterations
occur after 2-3 weeks (17), namely an increase in
intratubular pressure, and consequently an extension of the
tubule walls (31), epithelial tubular cell damage (72) and
subsequently a significant increase in renal fibrosis
indicators as inflammation mediated by macrophages (44,
74) and myofibroblasts (72). These cells produce cytokines
and growth factors that trigger an inflammatory process in
the kidney after UUO, inducing ECM deposition and cell
apoptosis. Furthermore, oxidative stress and the renin–Ang
II system play an important role in the overexpression of
pro-inflammatory cytokines in the UUO. In this sense, it is
fully established that TGFβ and NFĸB play a central role in
stimulating ECM production and in the inflammatory
process after UUO, respectively (72). The pro-inflammatory
kinin B1 receptor contributes to the development of UUO-
induced renal inflammation and consequently renal fibrosis.
In this way, Klein and colleagues (2009) showed that kinin
B1 receptor blockade significantly reduced the progression
of evident renal fibrosis in the UUO animal model. It seems
that this effect was in part provoked by a mechanism related
with the inhibition of CTGF and chemokine expression by
resident renal cells and without altering TGFβ expression
(74). Nevertheless, Wang and colleagues demonstrated that
kinin B1 receptor deletion reduced renal fibrosis while
improving expression of anti-inflammatory factors (heme
oxygenase-1 and interleukin-10) and reducing that of the
pro-inflammatory factors (TGFβ and interleukin-6) (44).
These results demonstrate that B1 receptor blockade reduces
renal fibrosis by modifying the expression of the immune
components, however certain effects/processes involved
remain to be determined.
An imbalance between vasoconstricting and vasodilating
substances may demonstrate haemodynamic changes
observed in the UUO model. This leads to the activation of
the plasma and renal renin–angiotensin–aldosterone system,
triggering subsequent pathological alterations through the
activation of TGFβ and NFĸB (75), the infiltration of immune
cells, fibrosis and renal hypoperfusion (31), and the
overexpression of CTGF (74). Indeed, as demonstrated in
several studies, renal Ang II is the crucial mediator of the
renal response to UUO, including inflammation, apoptosis,
interstitial fibrosis (17, 31, 75, 76), and increased fibroblast
expression (76). In a study by Kellner and colleagues, the
losartan angiotensin receptor antagonist considerably reduced
renal injury in the UUO model, improving apoptosis, renal
fibrosis, fibroblast and macrophage expression infiltration,
and thus demonstrating the effectiveness of this type of
treatment. About 50% of the renal alterations were not
affected by this treatment, indicating that there are other
factors in the development of renal injury in UUO. However,
these facts suggest that Ang II is responsible for around 50%
of the renal fibrotic response in UUO (76). Total UUO is a
pathological condition that causes tubular atrophy,
proliferation and apoptosis of the epithelial tubular cells,
macrophage infiltration, epithelial–mesenchymal transition,
interstitial cell infiltration, ECM deposition, collagen I
deposition and an accumulation of fibroblasts and
myofibroblasts (31). Lin and colleagues identified the
pericytes and fibrocytes as two sources of collagen I in the
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UUO of renal fibrosis (41), also showing that pericytes are
the source of myofibroblasts, highlighting the key role that
pericytes play in the development of renal fibrosis (41, 77).
In another study, absence of tumour necrosis factor-like weak
inducer of apoptosis (TWEAK) delayed the accumulation of
myofibroblasts and reduced ECM deposition in the UUO
mouse model. On the other hand, TWEAK overexpression
promoted renal fibrosis in mice without any kidney damage
(48). These results showed the fibrotic actions of TWEAK
that should be further investigated in order to understand the
mechanisms of a chronic persistent kidney injury model such
as the UUO model.
However, in this model, the recovery time following the
removal of the obstruction is inversely proportional to the
duration of the obstruction. On the one hand, in the UUO,
one of the first consequences of peritubular capillary
destruction, tubular atrophy and progressive renal
insufficiency is renal interstitial matrix accumulation.
However, on the other hand, renal inflammation leads to
glomerular and tubular damage in some nephrons, which in
turn leads to the damage of the remaining nephrons,
demonstrating that interstitial fibrosis is a secondary
expression of the disease (17).
Animal UUO models can be used in research to obtain
new therapeutic options for the more effective treatment of
renal fibrosis, e.g. mouse models, which have the advantage
of genetic manipulation of species (31). This is especially so
since this model has a rapid time course (6), does not use
exogenous toxins, lacks the ‘uremic’ environment, allows for
variations in the severity, timing, and duration of obstruction
(17), has good reproducibility, easy performance, availability
of the contralateral kidney as a control factor and is specific
strain independent (23). However, this model does have
some deficiencies, for example, the incapacity to monitor
changes in renal function, because the unobstructed
contralateral kidney offsets the loss in renal function (6), and
as it is realized with acute injury, may not be indicated for
the study of all conditions of renal fibrosis (4).
Ischaemia-reperfusion. The ischemia-reperfusion model is
performed in rats through median abdominal incision: the
left kidney is laid bare and the renal artery is ligated for 20
or 45 min in Wistar rats (29), and in C57BL/6 mice by 45 or
60 min of unilateral kidney ischemia (78). After one day, the
right kidney is removed via a dorsal incision to eliminate the
compensatory effects of the contralateral kidney. Kidney
samples from the rats taken 20 weeks after 20 and 45 min
ischaemia did not show significant interstitial fibrosis. Some
kidney samples exhibited atrophic tubules and revealed a
slightly thickened tubular basement membrane (29). Takada
et al. similarly demonstrated that the morphological changes
occurring predominantly between 20 and 40 weeks after
renal ischaemia are glomerulosclerosis and interstitial
fibrosis (79). Ischemia duration is also very important since
the almost-complete recovery of renal function and
morphology has been observed in rats 4 weeks after 30 min
ischaemia (80).
Spontaneous Models of Renal Fibrosis
There are several references in literature indicating that certain
mouse and rat strains may be more vulnerable to the
development and progression of renal disease and provide the
opportunity to investigate new mechanisms and new genes
that lead to spontaneous renal fibrosis. Thus, genetic
background plays an important role in the response to renal
injuries (65, 81). Wistar-Kyoto (WKY)/NCrj and ACI/NMs
rats are resistant to glomerulosclerosis, and male PVG/c rats
are totally resistant to glomerulosclerosis. On the other hand,
male Wistar rats are predisposed to the spontaneous
development of glomerulosclerosis, and approximately 100%
of Buffalo/Mna strain rats spontaneously develop
glomerulosclerosis over time (65) (Table III).
Buffalo/Mna rats. Between 2 and 4 months of age
Buffalo/Mna rats spontaneously develop podocyte
alterations, proteinuria, but without verification of sclerotic
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Table III. Spontaneous models used for renal fibrosis study.
Animals                     Strain/gender/age                                            Protocol                                                                  Results (reference)
Buffalo/Mna                 Buffalo/Mna/                     Kidneys from healthy LEW.1W (RT1u)               Proteinuria decreased in healthy kidneys grafted 
                                         6 months                       were grafted into 6-month-old proteinuric               into Buffalo/Mna recipients. Buffalo/Mna rats 
                                                                                Buffalo/Mna (RT1u) using a protocol of                    are suitable for the study of renal fibrosis 
                                                                        tolerance stimulation by donor-specific transfusion         and an interesting animal model for relapsing 
                                                                                                                                                                     segmental glomerulosclerosis in humans (47)
Munich Wistar           Munich Wistar               Diuresis experiments and fibrosis evaluation                   Data suggests that male Munich Wistar 
Frömter                   Frömter and Wistar/                     were performed in these animals                              Frömter rats spontaneously developed 
                                  ♀/♂/12-14 weeks                                                                                                         proteinuria and glomerulosclerosis with
                                                                                                                                                                           age, which appeared to be associated 
                                                                                                                                                                           with a lower number of nephrons (46)
glomeruli. At the age of 6 months, these animals had a few
sclerotic glomeruli in all sections of kidney examined. At 22
months of age, about 37.8-52.1% of the glomeruli became
sclerotic (82). These rats are suitable for use as animal
models to investigate renal fibrosis in humans (23).
Munich. Munich Wistar Frömter rats have a congenital
deficit with approximately 30-50% fewer nephrons than
normal, and structural changes (sclerosis) that develop
spontaneously with age (23). By the age of 10 weeks, these
rats develop proteinuria, and by week 35 the kidneys
demonstrate marked glomerulosclerosis (83). In these
animals, aging is also associated with a progressive increase
in blood pressure. This situation is more noticeable in
females than in males. However, males and females have a
similar glomeruli number per kidney. This gender-related
difference can be explained by the higher single nephron
filtration rate and glomerular volume verified in males when
compared to females (46, 83). These rats are animal models
to investigate renal fibrosis in humans; they allow us to study
the progression of renal disease associated with a reduction
in the number of nephrons (23, 46).
Genetically Modified Models of Renal Fibrosis
Renal fibrosis is much more difficult to induce in mice than
in rats, since mice demonstrate greater resistance to
experimental techniques. Thus, it is important to develop a
mouse model in which renal fibrosis can be induced by a
simple and unique procedure (84). Here, we describe four
animals genetically modified for this purpose (Table IV).
Transgenic mouse strain (Nep25). Nep 25 mice exhibit
genetically modified podocytes expressing a toxin receptor,
being selectively diminished by single intravenous injection of
anti-Tac (Fv)-PE38 (LMB2), a specific toxin, which led to
selective and irreversible damage in the podocytes. Thus, the
severity of disease can be controlled by the dose of toxin
administered and knowledge of the exact time and location of
the onset of the disease. After this injection, transgenic mice
in vivo 31: 1-22 (2017)
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Table IV. Genetic models used for renal fibrosis study – drugs evaluated and their efficacy.
Animals                        Strain/gender/                             Protocol                                          Drugs and                                Results and therapeutic 
                                        age/weeks                                                                              compounds evaluated                            effects (reference)
Nep 25 mice                   Nep 25/♀/                    LMB2 1.25 to 50 ng/g                                      -                                   Nep 25 mice dose-dependently 
                                       6-15 weeks                 i.v., data were performed                                                                     developed proteinuria, glomerular
                                                                                      for 28 days                                                                                     injury and renal fibrosis (84)
HIVAN                    HIVAN transgenic          Twenty-four sets of these            2.5 mg Flavopiridol/kg or an          Flavopiridol improved the focal 
transgenic                Tg26/heterozygous               groups entered and                 equivalent volume of vehicle            glomerulosclerosis in HIVAN 
mice                         transgenic and non-             completed the 20-day                 i.p. every 12 h for 20 days                     transgenic mice (104)
                                  transgenic/21 day            drug treatment protocol. 
                                                                          Chemical and histological 
                                                                           analyses were performed 
                                                                                   after treatment
Transgenic                 Adult (12 to 20          Transgenic mice expressing                                 -                                In normal kidneys, both podocytes 
mice expressing        weeks) or young            EGFP in cells producing                                                                        and pericytes produce Coll1a1
EGFP                          (P12 – neonates         coll-GFP. This mouse model                                                                     transcripts, and that in fibrotic 
                                 12 days after birth)                 is used to study                                                                                      kidneys, Coll1a1-GFP  
                               C57BL/6 or coll-GFP         collagen-producing cells                                                                          expression indeed identifies 
                                                                                 in kidney disease                                                                                        myofibroblasts (41)
Collagen-                  Collagen-receptor              Ddr1/Col4a3 double-
receptor                   deletion Ddr1/both         knockouts were compared                                   -                                 Absence of DDR1-expression in 
deletion Ddr1                sexes/7.5 or             to Col4a3−/− mice (129/Sv)                                                                          the kidney reduced renal 
                                        9.5 weeks              with 50% or 100% expression                                                                   fibrosis and inflammation (98)
                                                                        of DDR1, wild-type controls 
                                                                          and to Ddr1−/− Col4a3+/+
                                                                           controls for over 6 years
AT1a receptor-            AT1a receptor-          These animals were subjected                                -                               Results showed that the alterations 
deficient                   deficient C57BL/6            to UUO. Kidneys were                                                                     indicative of renal fibrosis observed 
C57BL/6 mice              /♀/10 weeks/           harvested at 2, 5, and 10 days                                                               in receptor-deficient AT1a C57BL/6 
                                          25g-35g                  for histological evaluation                                                                          mice were lower than those 
                                                                                                                                                                                           detected in mice with UUO (75)
i.v.: Intravenous; i.p.: intraperitoneal; Nep25: transgenic mouse strain; HIVAN: HIV-associated nephropathy; coll-GFP: collagen type I-α1 transcript;
DDR1: discoidin domain receptor 1; EGFP: enhanced green fluorescent protein; UUO: unilateral ureteral obstruction; AT1: angiotensin II type-1.
dose-dependently developed proteinuria and glomerular damage
and subsequently renal fibrosis (84). Renal fibrosis in these
transgenic mice and renal human fibrosis have similarities, and
they can therefore be used to study podocytopathies (23).
HIV-associated nephropathy (HIVAN) transgenic mouse model.
The HIVAN transgenic mouse model was developed using
transgenic 26 mice (Tg26) with a defective HIV provirus as the
integrated transgene (23, 85). HIVAN may be considered a
rapidly progressive form of focal segmental glomerulosclerosis
(86). At 24 days of age, these animals displayed proteinuria and
HIV-specific gene expression in the kidneys, and between 2 and
6 months of age a high mortality rate (20%) and slight focal
glomerulosclerosis were proven. Moribund animals demonstrate
considerable glomerulosclerosis, microcystic tubular alteration
and tubular epithelial degeneration, and interstitial nephritis,
changes very similar to those found in human HIVAN (23, 85).
Based on this Tg26 mouse model, a rat HIVAN model has also
been developed which shows a more markedly expressed HIV
transgene, however without glomerular collapse (23).
Coll-green fluorescent protein transgenic mice. Transgenic
mice were generated expressing enhanced green fluorescent
protein (EGFP) in cells producing the collagen type I-α 1
(Coll1a1) transcript (coll-GFP mice). Collagen I-α1 is the
most abundant protein in collagen-I fibrils. These mice
express a single copy of 3.5 kb of the 5’ Coll1a1 promoter,
0.5 kb of the 3’ uncoded region and four upstream enhancers,
driving EGFP expression, and have been shown to label
collagen-I α1-producing cells with high sensitivity and
specificity. This model is used to study collagen-producing
cells in renal fibrosis (41).
AT1 receptor-deficient mice. Angiotensin AT1a receptor-
deficient C57BL/6 (mutant) mice have a targeted
replacement of AT1a loci by the lacZ gene. These animals
enable us to clarify the importance of AT1a-mediated signal
transduction pathways in the pathophysiology of renal
diseases, especially tubulointerstitial injury. Therefore,
C57BL/6 (mutant) mice are useful in the study of the
specific function of AT1a receptor (87).
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Table V. In vitro models used for renal fibrosis study – drugs evaluated and their efficacy.
Cells                                                            Protocol                                                 Drugs and                                        Results and therapeutic 
                                                                                                                          compounds evaluated                                    effects (reference)
Cultured rat                          Rat mesangial cells were obtained                                   -                                     Ang II induces TGFβ production and 
mesangial cells                        from intact glomeruli from 4-6                                                                           secretion by mesangial cells and TGFβ 
                                                 week-old Sprague-Dawley rats                                                                           in turn stimulates ECM production (12)
Cultured rat kidney                                NRK52E line                                                     -                                       Ang II induces the activation of the
tubular epithelial cell                                                                                                                                            Smad2/3 and mitogen-activated protein 
                                                                                                                                                                             kinase pathways, as well as the expression 
                                                                                                                                                                                 of CTGF, TGFβ1, and collagen I (30)
Cultured rat                          Rat mesangial cells were obtained          Pre-incubation with a selective        Pre-treatment with eplerenone or Y27632
mesangial cells                            from Sprague-Dawley rats/                     mineralocorticoid receptor                  prevented the aldosterone-induced 
                                                   stimulation with aldosterone             antagonist eplerenone (10 μmol/l)              cell hypertrophy, promoting an 
                                              (1 nmol/l) induced myofibroblastic       or a specific Rho-kinase inhibitor,          increase in collagen gene expression
                                               differentiation and collagen gene                    Y27632 (10 μmol/l)                            via the Rho-kinase dependent 
                                                expression in rat mesangial cells                                                                                       signalling pathway (88)
Cultured mice renal               Mice renal interstitial fibroblast                                     -                                           Results suggests that TWEAK 
fibroblast cells                       cells originally isolated from SJL                                                                             overexpression may promote renal 
                                               mouse kidney/Murine embryonic                                                                            fibrosis by increasing inflammatory
                                            fibroblasts were isolated from mouse                                                                                activity and proliferation in 
                                                embryos at 10 days post-coitum                                                                                   cultured renal fibroblasts (48)
Cultured murine                       Murine embryonic fibroblasts          Cells were treated with cyclosporine                 Cyclosporine A treatment 
embryonic fibroblasts                      from wild-type and                         A (2, 4, and 8 μM) for 48 h                     increased heme oxygenase-1 
and normal rat kidney                    NRF2-deficient mice                     and NRK52E cells were treated              expression in an NRF2-dependent
tubular epithelial cells                           and NRK52E                            with sulforaphane (an activator                mode in normal rat kidney cells 
                                                                                                                        of NRF2) for 24 h then                      as well as in murine fibroblasts. 
                                                                                                                         incubated with vehicle                    Genetic inhibition of NRF2 in these 
                                                                                                                       (ethanol) or cyclosporine                       cells intensified alterations in 
                                                                                                                            A (8 μM) for 48 h                         cyclosporine A-induced epithelial–
                                                                                                                                                                                mesenchymal transition indicators (97)
Ang II: Angiotensin II; TGFβ: transforming growth factor-β; ECM: extracellular matrix; NRK52E: normal rat kidney tubular epithelial cells; CTGF:
connective tissue growth factor; TWEAK: tumour necrosis factor-like weak inducer of apoptosis; NRF2: nuclear factor E2-related factor 2.
In Vitro Models 
Nearly all intrinsic renal cells have been widely studied to
assess specific mechanisms and signal pathways of renal
fibrosis development. However, the results are incomplete,
usually based on very specific aspects concerning only one
cell type and very different from the complexity verified in
renal fibrosis responses when studied in animal models (23)
(Table V).
Cultured rat mesangial cells. Rat mesangial cells are used to
study the physiopathological processes of renal disease in
particular renal fibrosis, for example, the action of Ang II on
TGFβ production and secretion by mesangial cells and the
potential roles of Rho-kinase in aldosterone-induced
mesangial cell hypertrophy (12, 88).
Cultured mouse renal fibroblast cells. Mouse renal fibroblast
cells are used to study the molecular and cellular mechanisms
promoting renal fibrosis. Cultured renal fibroblast cells can be
used to evaluate the effect of tumour necrosis factor superfamily
cytokines in the induction of the renal fibrosis process. Ucero
and colleagues demonstrated that TWEAK induced
inflammatory activity and proliferation in renal fibroblast cells,
and this action has an RAS-dependent pro-proliferative and
NFĸB-dependent proinflammatory effects (48).
Effective Treatments and New 
Perspectives of Research
A very important factor in the preservation of renal function is
the control of hypertension and hyperglycaemia (2). In humans,
failure of kidney function caused by fibrosis generally happens
many years after the onset of diabetes or recurrent infections.
Although it is not possible to reproduce this phase in animal
studies, the use of animal models for renal fibrosis allows for
the evaluation of drug efficacy in the treatment of renal fibrosis
and also the pathogenesis of this disease (25). However, there
are few or no drugs with the capacity to prevent the fibrotic
process in experimental and human CKD (89), not only in
monotherapy but also with a combination of therapies, perhaps
because renal fibrosis is a complex process that involves
several cell types and mediators (90).
Treatments that target the renin–angiotensin–aldosterone
system inhibition, carried out with two types of drugs:
angiotensin-converting enzyme inhibitors and angiotensin
receptor antagonists, are extremely effective in reducing
proteinuria, CKD progression and renal fibrosis in humans and
experimental models (1, 5, 12, 19). Indeed, Ang II is a
principal mediator in the pathogenesis of renal disease (8). The
use of higher doses of these two drugs can more effectively
reduce fibrosis (32), and the benefits of this treatment are
independent of blood pressure reduction (2). One of the
factors leading to these effects by the blockage of the renin
angiotensin system is indeed the reduction of the activity of
TGFβ (14, 20) and also platelet-derived growth factors and
PAI1 (5). In a study carried out in humans, losartan, an Ang
II receptor blocker, diminished PAI1 in cyclosporine-treated
renal graft recipients. Ang II blockage and PAI1 diminution
may be an important action in preventing renal fibrosis (91).
Currently, Ang II inhibition is clinically considered to be the
most effective therapeutic intervention for preventing or
reducing the development of most renal diseases (17).
Although angiotensin–converting enzyme inhibition has
widely recognized clinical benefits on the development of
renal sclerosis, it is not equally effective at all stages of renal
fibrosis, i.e. it is more effective in the earlier stages of
sclerosis than in its advanced stages (5) (Figure 2).
Treatment with Rehmannia glutinosa inhibits the
progression of glomerulosclerosis by reducing TGFβ mRNA
expression and type IV collagen accumulation and is likely
to prevent the presence of interstitial fibrosis and
mononuclear cell infiltration (43). Pirfenidone, an anti-
fibrotic molecule, attenuates renal fibrosis in the UUO model
by reducing the level of TGFβ and the synthesis of collagen
in the renal tissue, suggesting that pirfenidone may be applied
as a treatment of renal fibrosis progression (92). However,
despite the fact that anti-TGFβ therapies are associated with
improved renal fibrosis (2, 7), it should be cautiously selected
for regression of renal fibrosis because TGFβ is involved in
the glomerular self-defence system that limits inflammation
in renal injuries (20). On the other hand, a combination of
TGFβ antibody with angiotensin-converting enzyme
inhibitors offers superior nephroprotective effects than single
treatments in that it normalizes blood pressure, proteinuria
and led to regression of glomerulosclerosis and tubular
injuries in rats (20). Blockade of the kinin B1 receptor is
another promising antifibrotic therapy for renal fibrosis in
animal models of obstructive nephropathy (44, 74). In another
study, it was verified that the therapeutic combination of
mycophenolate mofetil (immunosuppressive agent) and
benazapril (angiotensin-converting enzyme inhibitor) was
more effective in the treatment of renal fibrosis than
mycophenolate mofetil and benazapril alone in 5/6
nephrectomized rats (9). Treatment with fasudil, a specific
Rho-kinase inhibitor, significantly improved aldosterone-
induced renal fibrosis and increased collagen, TGFβ, and
CTGF expression as well as SMAD2/3 activity in the kidneys
of rats which had undergone a right uninephrectomy (93). In
another study, the effects of aldosterone were diminished by
pre-treatment with a mineralocorticoid receptor antagonist
and Rho-kinase inhibitor (88). This type of study, with a
combination of two or more drugs, showed more effective
results in several models of renal fibrosis, and should be
considered as potential treatments. Nevertheless, further
studies in animal models are required to confirm whether
in vivo 31: 1-22 (2017)
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TGFβ and aldosterone blockers or other agents are beneficial
for combatting the progression of renal fibrosis, and to assess
whether these therapies can actually be investigated in human
clinical trials because it is evident that Ang II blockade alone
is not sufficient for preventing or regressing renal fibrosis.
Yang and colleagues showed that the ability to block
SMAD3 but not SMAD2, and to inhibit Ang II-mediated
CTGF and fibrotic responses, may also be an alternative
therapy for preventing the progression of renal fibrosis (30).
It seems possible to inhibit matrix deposition and renal
fibrosis within the kidney by blocking CTGF expression
without affecting TGFβ expression. Furthermore, CTGF
blockade promotes some anti-profibrotic properties similar to
TGFβ blockade, however, it probably does not share the
immunomodulatory properties of TGFβ (36). In another
study, it was demonstrated that CTGF siRNA blocked the
epithelial–mesenchymal transition in rat kidney grafts
undergoing chronic allograft nephropathy (94). CTGF
inhibition may be considered a potential therapy for
preventing renal fibrosis.
Active vitamin D and its analogous elements reduce renal
fibrosis by attenuating glomerulosclerosis and interstitial
fibrosis. The various actions of active vitamin D on kidney
function, depending on the nature and aetiologies of the CKD
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Figure 2. Effective and new treatments of renal fibrosis. PDGF: Platelet-derived growth factors; PAI1: plasminogen activator inhibitor-1; CTGF:
connective tissue growth factor; DDR1: discoidin domain receptor 1; TGFβ: transforming growth factor-β; NFĸB: nuclear factor-ĸB; NADPH:
nicotinamide adenine dinucleotide phosphate; mRNA: messenger ribonucleic acid.
animal models, consist of the regulation of the renin–
angiotensin system, anti-inflammation, podocyte defence,
hepatocyte growth factor induction and preservation of tubular
epithelium by blocking epithelial–mesenchymal transition.
Supplementary treatment with active vitamin D can thus
improve renal function in individuals with CKD (73).
Treatment with vitamin E significantly reduced the degree
of kidney structural damage in the 5/6 nephrectomized rats,
showing that treatment with vitamin E reduces
glomerulosclerosis in 5/6 nephrectomized rats (95). Perhaps
this is associated with the fact that vitamin E somewhat
attenuates the rise in glomerular and mesangial diacylglycerol
content that mediates the overactivation of protein kinase C
(primary mediator of renal dysfunction in diabetic rats).
Vitamin E treatment also attenuates glomerular and mesangial
TGFβ activity. Ruboxistaurin, a drug which inhibits this
isoform of protein kinase C, was tested in diabetic rats, and
has been observed to reduce the mesangial expression of
TGFβ mRNA and to some extent suppress glomerulosclerosis
(2). In another study, Wang and colleagues showed that the
Fuzheng Huayu formula and vitamin E have an inhibitory
effect on renal fibrosis by reversing tubular epithelial–
mesenchymal transition in renal interstitial fibrosis induced
by HgCl2 in rats. Additionally, the Fuzheng Huayu formula
directly reduced TGFβ-induced epithelial–mesenchymal
transition in human proximal tubular epithelial cells. This
action is probably potentiated, at least in part, by reducing
SMAD2/3 phosphorylation (49). Indeed, it appears that in
rats, vitamin E has a protective effect on HgCl2-induced renal
interstitial fibrosis (49, 50). However, it is worth noting that
a meta-analysis of 136,000 subjects in 19 clinical trials
indicated that a high dosage (400 IU/day) of vitamin E
supplements increased all-cause mortality in humans, limiting
the efficacy of this treatment in humans (96).
Halofuginone, a collagen I inhibitor, showed a beneficial
decrease in the progression of renal fibrosis in the
experimental model of 5/6 renal mass ablation, and this was
independent of blood pressure alterations (89).
The NFĸB family can directly and indirectly stimulate
cellular actions leading to tissue fibrosis. Cytokine-medicated
counter-regulatory mechanisms that block NFĸB activation
might possibly prevent renal disease initiation/progression
(15). Other types of treatment may concern the inhibition of
NADPH oxidase activity, an important mediator of renal
fibrosis. The use of agents with antioxidant properties appears
to have benefits in the regression of renal fibrosis in
nephropathy rats (2).
Extracellular factors and intracellular mediators that
control epithelial–mesenchymal transition have been
recognized as a possible alternatives in combat against the
progression of renal fibrosis (13). Shin et al. suggest that
treatment with small-molecule nuclear factor E2-related
factor 2 (NRF2)-specific activators might be an alternative
therapy for the prevention or regression of the epithelial–
mesenchymal transition fibrosis process evidenced by
oxidative stress (97).
Collagen-receptor: discoidin domain receptor 1 (DDR1) is
involved in the pathogenesis of Alport syndrome, including
renal inflammation and fibrosis. The inhibition of this receptor
seems to represent a new therapeutic strategy in the progression
of renal fibrosis in the future. This nephroprotective effect on
the loss of DDR1 may be due to the down-regulation of
profibrotic cytokines TGFβ and CTGF (98).
Chaetomellic acid A, a selective inhibitor of HRAS
farnesylation (99) tested in mice who had undergone UUO,
showed a promising action on the reversal of renal fibrosis
(100). In addition, our research team demonstrated that
inhibition of RAS activation with chaetomellic acid A may
be a future strategy in the prevention of renal fibrosis (101).
Another alternative treatment for renal fibrosis might be
the use of stem or progenitor cells to treat or restore the
function of the damaged kidney. This type of treatment allows
us not only to halt the progression of the disease but also to
restore renal function, however, we need to confirm several
mechanisms of the stem or progenitor cell action (102).
It is currently thought that cultured cells with features of
glomerular epithelial differentiation have an important action
on the development of renal damage due to the effects of
plasma proteins on podocyte function. In this way, proteins,
beyond being a simple indicator of renal damage, can be
toxic to the kidney (19).
Through latest-generation confocal and multiphoton
microscopy, and with the help of computer programmes, we
are able to identify differences within the glomerular network
organization that emerge during sclerosis regression, which
allows for the identification of changes in cell and gene
expression (19). Despite the progress achieved in several
studies with different types of treatments and drugs, no drugs
presently exist for the effective treatment of renal fibrosis (25).
Conclusion
CKD has many different genetic and environmental causes
and several pathological effects such as renal fibrosis, hence
this is why it is very important to use different animal
models. These models have provided important insight into
the pathogenesis of renal fibrosis. The use of appropriate
models for the study of renal fibrosis may provide
information that provides an understanding of the pathogenic
mechanisms of the causes and progression of the disease, as
well as potential therapeutic interventions. In particular, the
expansion of experimental models for renal fibrosis has
allowed the productive investigation of factors associated
with cellular and molecular responses to damage caused by
renal disease and the fibrotic sequence of events. There is a
variety of animal models which display characteristics and
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aspects of the relevant human renal disease. Among the many
animal models used to study renal fibrosis, some are more
commonly used than others and therefore there is little
information available on the less-studied models. The most
commonly used models to investigate renal fibrosis are UUO
and 5/6 renal mass reduction, perhaps because they have
more advantages and similarities to studies of renal fibrosis
in humans, or simply because they have been the most used
in recent years. On the other hand, in our research, we found
that in many investigations, not all methods and materials are
disclosed. For these reasons, many of the renal fibrosis
models, especially those that are used less often, are very
difficult to reproduce.
The most frequent pathophysiological changes in humans
have been successfully reproduced in animal models, which
increases our understanding of human pathology and
enables us to develop new animal models and also evaluate
new therapies. However, no model exactly mimics all the
alterations caused by the progression of renal disease in
humans such as renal fibrosis, because the factors associated
with this disease are not yet completely understood. Due to
the different aetiological factors of this disease, it is
necessary to evaluate precise experimental data because the
analysis of the results obtained in the animal models could
lead to wrong conclusions about the pathophysiology of
renal fibrosis in humans. Thus, the extrapolation of
outcomes from animal models to humans should consider
that the mechanisms of fibrosis and efficacy of interventions
and treatments differ considerably with different models of
renal fibrosis. Perhaps the greatest challenge is to
understand how to adapt the experimental innovations to
clinical reality. Currently, there are no effective treatments
that prevent the progressive destruction of nephrons or
avoid the formation of scar tissue. Nevertheless, the
potential of the renin–angiotensin system in renal lesions
that leads to ECM and sclerosis should be emphasized by
the effectiveness of therapies that aim to inhibit its various
actions. It is therefore important to improve our knowledge
of the cellular and molecular stages of the development of
renal fibrosis in order to determine specific markers that
will allow for appropriate intervention in the progression of
CKD, and perhaps even achieve a regression/ elimination of
renal sclerosis.
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